Rafarma Pharmaceuticals Inc (RAFA)
Rafarma Pharmaceuticals Inc. is a common stock listing on OTC Markets tied to a healthcare company focused on pharmaceuticals. The company develops and sells drugs in Russia, including generic antibiotics, cephalosporin-based products, specialty pharmaceuticals, and anti-cancer medicines. Its product forms include injections, ampoules, pediatric suspensions, tablets, and capsules, and its portfolio also includes treatments for accidental wounds, inflammatory eye diseases, and immunological disorders. Rafarma has also announced a collaboration with PlantEXT Ltd. to research and manufacture medical cannabis suppositories for patients with inflammatory bowel disease. The company was previously known as Johnston Acquisition Corp. and adopted its current name in October 2012. It is based in Sandy, Utah, with manufacturing and distribution operations in Russia, and as of October 19, 2020, it has operated as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-RAFA
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
3.072 M
|
—
|
—
|
—
|
—
|
—
|
—
|